An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
2015년 12월 18일 업데이트: Hoffmann-La Roche
An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.
This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first line therapy for at least 12 months and without disease progression for at least 12 months.
Data will be collected retrospectively (from the diagnosis to the inclusion in the study) and for 18 months from study start.
연구 개요
상태
완전한
정황
연구 유형
관찰
등록 (실제)
228
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Aix En Provence, 프랑스, 13616
-
Aix En Provence, 프랑스, 13617
-
Ajaccio, 프랑스, 20176
-
Amiens, 프랑스, 80090
-
Antony, 프랑스, 92166
-
Arras, 프랑스, 62012
-
Bastia, 프랑스, 20200
-
Bayonne, 프랑스, 64100
-
Beauvais, 프랑스, 60021
-
Besancon, 프랑스, 25030
-
Beziers, 프랑스, 34535
-
Bobigny, 프랑스, 93009
-
Bordeaux, 프랑스, 33077
-
Bordeaux, 프랑스, 33030
-
Boulogne-billancourt, 프랑스, 92100
-
Bourg En Bresse, 프랑스, 01012
-
Brest, 프랑스, 29609
-
Caen, 프랑스, 14076
-
Chambery, 프랑스, 73011
-
Chateauroux, 프랑스, 36019
-
Cherbourg Octeville, 프랑스, 50102
-
Clermont Ferrand, 프랑스, 63050
-
Clermont Ferrand, 프랑스, 63011
-
Creteil, 프랑스, 94010
-
DAX, 프랑스, 40107
-
Dijon, 프랑스, 21079
-
Eaubonne, 프랑스, 95602
-
Evreux, 프랑스, 27025
-
Grenoble, 프랑스, 38000
-
La Chaussee St Victor, 프랑스, 41260
-
La Roche Sur Yon, 프랑스, 85925
-
La Tronche, 프랑스, 38700
-
Le Coudray, 프랑스, 28630
-
Lille, 프랑스, 59020
-
Lille, 프랑스, 59003
-
Limoges, 프랑스, 87042
-
Longjumeau, 프랑스, 91161
-
Lorient, 프랑스, 56322
-
Lormont, 프랑스, 33310
-
Lyon, 프랑스, 69373
-
Lyon, 프랑스, 69337
-
Marseille, 프랑스, 13285
-
Marseille, 프랑스, 13273
-
Marseille, 프랑스, 13004
-
Metz, 프랑스, 57045
-
Montivilliers, 프랑스, 76290
-
Mougins, 프랑스, 06250
-
Nancy, 프랑스, 54100
-
Narbonne, 프랑스, 11108
-
Nice, 프랑스, 06189
-
Osny, 프랑스, 95520
-
Paris, 프랑스, 75970
-
Paris, 프랑스, 75651
-
Paris, 프랑스, 75475
-
Paris, 프랑스, 75674
-
Paris, 프랑스, 75231
-
Paris, 프랑스, 75571
-
Paris, 프랑스, 75230
-
Paris, 프랑스, 75181
-
Perigueux, 프랑스, 24000
-
Reims, 프랑스, 51057
-
Romans Sur Isere, 프랑스, 26102
-
Rouen, 프랑스, 76000
-
Rouen, 프랑스, 76044
-
Saint Brieuc, 프랑스, 22015
-
Saint Gregoire, 프랑스, 35768
-
Saint Jean, 프랑스, 31240
-
Senlis, 프랑스, 60309
-
Soyaux, 프랑스, 16800
-
St Cloud, 프랑스, 92210
-
St Germain En Laye, 프랑스, 78105
-
St Michel, 프랑스, 16470
-
St Priest En Jarez, 프랑스, 42271
-
Strasbourg, 프랑스, 67010
-
Toulon, 프랑스, 83056
-
Toulouse, 프랑스
-
Toulouse, 프랑스, 31076
-
Troyes, 프랑스, 10003
-
Valence, 프랑스, 26953
-
Vannes, 프랑스, 56001
-
Verdun, 프랑스, 55107
-
Villejuif, 프랑스, 94805
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
샘플링 방법
확률 샘플
연구 인구
Patients (triple negative or HR+) with HER2- metastatic or locally advanced breast cancer, treated with Avastin 1st line for at least 12 months and without progression for at least 12 months.
설명
Inclusion Criteria:
- Adult patients, >/=18 years of age
- HER2-metastatic breast cancer or locally advanced breast cancer
- Patients with Avastin as first line therapy administered for at least 12 months
- Patients without disease progression after the beginning of Avastin treatment for at least 12 months
Exclusion Criteria:
- Patients not willing to give informed consent
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
보병대
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Who Were Disease-Free for at Least 12 Months After Initial Diagnosis
기간: From initial diagnosis to the diagnosis of metastatic disease (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Disease free interval was expressed in months: (Date of diagnosis of metastatic disease - Date of initial diagnosis + 1) / 30.4375.
Percentage of participants who were disease-free for at least 12 months were reported.
|
From initial diagnosis to the diagnosis of metastatic disease (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants Who Were Disease-Free for at Least 24 Months After Initial Diagnosis
기간: From initial diagnosis to the diagnosis of metastatic disease (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Disease free interval was expressed in months: (Date of diagnosis of metastatic disease - Date of initial diagnosis + 1) / 30.4375.
Percentage of participants who were disease-free for at least 24 months were reported.
|
From initial diagnosis to the diagnosis of metastatic disease (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Disease-Free Interval
기간: From initial diagnosis to the diagnosis of metastatic disease (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Disease free interval was expressed in months: (Date of diagnosis of metastatic disease - Date of initial diagnosis + 1) / 30.4375.
Disease free interval was observed retrospectively and assessed at inclusion period or baseline (the time after the retrospective phase and at the start of prospective phase).
|
From initial diagnosis to the diagnosis of metastatic disease (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Mean Age at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Menopausal Status at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Menopausal status included premenopausal and menopausal.
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG PS) at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on a 5 point scale: 0 equals (=) fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, but ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than [>] 50 percentage [%] of waking hours [h]), capable of all self care, but unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hours; 4= completely disabled, cannot carry on any selfcare, totally confined to bed or chair and 5=Dead.
Only participants that reported in any of the specified scale was reported.
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Mean Body Weight at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Mean Height at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Mean Body Mass Index (BMI) at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m^2).
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Breast Cancer (BRCA) Mutation at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Metastatic Disease at Identified Metastatic Sites at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Metastatic diseases were identified at bone, lung, liver, central nervous system, soft tissue, lymph nodes, skin, pleura and other sites.
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants Classified Based on Number of Metastatic Sites at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Percentage of participants that reported metastatic disease in less than or equal to (<=) 3 sites or greater than (>) 3 sites were assessed.
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Visceral Involvement at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Estrogen Receptors (ER) at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Progesterone Receptors (PR) at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Cross Results for Both ER and PR at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With HR Status at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Negative HER2 Status at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Mitotic Index (MI) at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
MI is an indirect measure of cell proliferation that has been demonstrated to be a strong predictor of outcome for several human and canine cancers.
Percentage of participants that reported a low, intermediate, high and unknown indices were included.
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Ki67 (MiB1) at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
The Ki67 (MiB1) a prognostic marker, is used to evaluate the proliferative activity of breast cancer.
Percentage of participants with < or >=10% and unknown were reported.
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Previous and Concurrent Disease at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants Who Received First-Line Endocrine Therapy at the Time of Local or Metastatic Progression
기간: At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
Time of local or metastatic progression is the time of advanced or metastatic diagnosis which was assessed at inclusion or baseline (the time after the retrospective phase and at the start of prospective phase).
|
At the time of Advanced or Metastatic Diagnosis (up to a maximum of 260 months, assessed retrospectively at Baseline)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)
기간: From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months , assessed retrospectively at Baseline)
|
Objective tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST).
Confirmed CR was defined as the disappearance of all target and non-target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions.
Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response.
Inclusion (baseline) here was the time after the retrospective phase and at the start of prospective phase.
|
From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months , assessed retrospectively at Baseline)
|
|
Percentage of Participants With Disease Progression or Death
기간: From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months , assessed retrospectively at Baseline)
|
Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
|
From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months , assessed retrospectively at Baseline)
|
|
Progression-Free Survival
기간: From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months, assessed retrospectively at Baseline)
|
Progression-free survival was defined as the time from first dose of bevacizumab to documented PD or death from any cause, whichever occurred first.
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
Inclusion (baseline) here was the time after the retrospective phase and at the start of prospective phase.
|
From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months, assessed retrospectively at Baseline)
|
|
Time to Progression
기간: From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months, assessed retrospectively at Baseline)
|
Objective tumor response was assessed using RECIST.
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD.
Time to progression was defined as the time from treatment start to PD. Participants who did not experience PD were censored from the last tumor assessment.
Time to progression was estimated using Kaplan-Meier and expressed in months.
Inclusion (baseline) here was the time after the retrospective phase and at the start of prospective phase.
|
From first administration of bevacizumab to inclusion in the study (up to a maximum of 42.8 months, assessed retrospectively at Baseline)
|
|
Percentage of Participants With Death
기간: From the first administration of bevacizumab to death from any cause (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
Overall survival (OS) was defined as the time between the first administration of bevacizumab and death from any cause and participants still alive at the end of the study were censored at the last consultation or last contact date.
|
From the first administration of bevacizumab to death from any cause (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
Overall Survival (OS)
기간: From the first administration of bevacizumab to death from any cause (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
OS was defined as the time between the first administration of bevacizumab and death from any cause and participants still alive at the end of the study were censored at the last consultation or last contact date.
|
From the first administration of bevacizumab to death from any cause (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
Duration of Bevacizumab as First Line Treatment
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
|
Percentage of Participants With Temporary Discontinuation
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
|
Percentage of Participants With Reasons for Temporary Discontinuation
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
|
Percentage of Participants With Definitive Discontinuation
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
|
Percentage of Participants With Reasons for Definitive Discontinuation
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
|
Percentage of Participants Who Maintained Bevacizumab Beyond the First Progressive Disease
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
|
|
Percentage of Participants Who Received Induction Therapy in Combination With Bevacizumab
기간: From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
From start of bevacizumab until 18 months after inclusion (up to a maximum of 60.8 months including retrospective and prospective treatment)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2011년 9월 1일
기본 완료 (실제)
2013년 11월 1일
연구 완료 (실제)
2013년 11월 1일
연구 등록 날짜
최초 제출
2011년 10월 24일
QC 기준을 충족하는 최초 제출
2011년 10월 26일
처음 게시됨 (추정)
2011년 10월 27일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2016년 1월 26일
QC 기준을 충족하는 마지막 업데이트 제출
2015년 12월 18일
마지막으로 확인됨
2015년 12월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)완전한피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
SB Istanbul Education and Research Hospital아직 모집하지 않음Thryoid cancer | parathyrıoid 선종
-
Jonsson Comprehensive Cancer CenterNovartis Pharmaceuticals모병전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center모병전립선 선암종 | 2기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Society for Endocrinology초대로 등록
-
Jonsson Comprehensive Cancer Center모병거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국